Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TRK 170

Next Previous
Drug Profile

TRK 170

Latest Information Update: 26 Jan 2016

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Toray
  • Class Antiulcers
  • Mechanism of Action Alpha4beta7 integrin antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Crohn's disease

Most Recent Events

  • 01 Apr 2014 Toray completes a phase II trial in Crohn's disease in Belgium, Bulgaria, Czech Republic, France, Hungary, Latvia, Netherlands, Norway, Poland, Romania, Serbia, Sweden and Ukraine (NCT01345799)
  • 27 May 2011 Phase-II clinical trials in Crohn's disease in Bulgaria, Czech Republic, Hungary, Latvia, Netherlands, Poland, Romania, Serbia and Ukraine (PO) after 27 May 2011

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top